NCT07348484Not yet recruiting
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
Diagnostic and Monitoring System for Chronic Kidney Disease Based on Urinary Biomarkers and Preventive Treatment With the SGLT2 Inhibitor Empagliflozin
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression. No investigational product is assigned, and medical practice or prescription patterns are not altered.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Instituto de Investigación Biomédica de Salamanca
- Diseases
- Chronic kidney disease
- NCT number
- NCT07348484
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Jan 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or recent renal replacement therapy or kidney transplantation
Other illness
- End-stage renal disease
- Allergy or intolerance to SGLT2i (for exposed cohort)
Other
- Participation in interventional trials that may affect outcomes
Who the study is looking for
- ≥18 years old
- Diagnosed with chronic kidney disease (KDIGO stages 2-4)
- Life expectancy ≥12 months
- Available clinical and laboratory data in the electronic medical record
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario De Salamanca Coordinator of this site? Confirm its status | Salamanca | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.